Effects of Post-COVID-19 on Quadriceps Femoral Muscle-tendon Unit

NCT04961255 | Unknown

• 1 other identifier: CAAE: 45043821.0.0000.8093
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

The physiological/biomechanical characteristics related to muscle and tendon architecture and their possible relationship with the loss of muscle strength and fatigue in patients who were infected with COVID-19 are totally unknown. The aim of this study is to evaluate inflammatory markers, the isometric maximum voluntary force of the knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, tendinous properties of quadriceps components, oxygen extraction, and body composition in participants after diagnosis with Covid-19 who had moderate and severe levels of involvement compared to a healthy control group.

Conditions

Post-COVID-19; Healthy Participants

Keywords

COVID-19; muscle; tendon; cytokines; electrodiagnosis; fatigue; strength; peripheral oxygen extraction

Outcome Measures

Primary Outcomes (12)

• Blood biomarkers

  Blood biomarkers including metalloproteinase 9, interleukin-6, interleukin-8 and interleukin-10, interleukin 1 beta, tumor necrosis factor alpha type, nitric oxide, as well as creatine kinase will be collected in blood samples by venipuncture in the vein brachial, in heparinized tubes with separating gel using the vacutainer system with ethylenediaminetetraacetic acid (EDTA). The samples will be stored and later analyzed using appropriate techniques.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Sit to stand test

  To carry out the test will be used a stopwatch and a chair with the back against a wall, seat height 43 cm from the floor and without armrest. The test consists of measuring how many times the participant can get up and sit down from a chair (counting as a movement) in a period of 30 seconds.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Electrodiagnostic stimulus test

  The quadriceps femoris, gastrocnemius, soleus and tibialis anterior muscles will be evaluated. At the muscle motor point, the values of rheobase, chronaxia and accommodation will be investigated.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Body composition

  Body composition will be estimated using dual x-ray absorptiometry. Fat mass and fat-free mass will be expressed in absolute values.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Muscle force

  Muscle force will be assessed by muscle force changes, based on the torque generated during maximum voluntary contraction.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Peripheral oxygen extraction

  The assessment of peripheral oxygen extraction will be performed both in rest and during voluntary contraction. The evaluation will be carried out by means of near-infrared spectroscopy (NIRS or near infrared spectroscopy).

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Surface electromyographic activity

  Electromyographic activity of each superficial component of the quadriceps muscle both in rest and during voluntary contraction.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Muscle architecture

  Muscle architecture analyzes will be performed using ultrasound at rest and during voluntary contraction. The muscle volume of the knee extensors, muscle thickness, pennation angle, fascicle length and muscle echogenicity will be evaluated.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Properties of the patellar tendon

  The morphological, material and mechanical properties will be evaluated based from the elongation of the patellar tendon during maximum voluntary contraction.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Muscle fatigue

  Quadriceps muscle fatigue will be assessed in each leg after consecutive maximal isometric voluntary contractions of the quadriceps muscle.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Assessment of perceived exertion during the fatigue protocol

  Assessment of perceived exertion will be analyzed before, during, and after the performance of maximum voluntary isometric contractions performed to analyze muscle fatigue using the BORG scale of perceived exertion.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

• Fatigue severity analysis

  Fatigue severity analysis will be assessed using the fatigue severity scale.

  Change from baseline 1 (days 21-30) to assessments 2 (days 31-90), 3 (days 91-180), and 4 (days 181 to 360) for groups composed of COVID-19 positive participants. The Control group will be assessed only at baseline.

Study Arms (3)

Control group

Healthy individuals will be evaluated only once throughout the study. Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated.

COVID-19 positive participants who had moderate symptoms group

These participants will be evaluated 4 times throughout the study. Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection. Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection. Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection. Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection. Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment.

COVID-19 positive participants who had severe symptoms group

These participants will be evaluated 4 times throughout the study. Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection. Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection. Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection. Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection. Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment.

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Female and male participants aged between 18 and 80 years who had tested positive for COVID-19 will be included in this study. In addition, the control group will include healthy participants who had not tested positive for COVID-19.

You may qualify if:

• Control group:
• \- The control group will include healthy participants, aged 18 and 80 years, who had not tested positive for COVID-19.
• COVID-19 positive participants who had moderate symptoms group:
• Female and male participants, aged between 18 and 80 years, who had Molecular test (RT-PCR) or serological test, which assesses whether the samples are reactive to immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies, positive for COVID-19;
• Presence of some of the following symptoms, without the need for hospitalization: dry cough, runny nose, sore throat, diffuse body pain, persistent hyperthermia, no hypoxemia.
• COVID-19 positive participants who had severe symptoms group:
• Female and male participants, aged between 18 and 80 years, who had Molecular test (RT-PCR) or serological test (which assesses whether the samples are reactive to IgM and IgG antibodies) positive for COVID-19;
• Presence of hypoxemia (peripheral oxygen saturation - SPO2 ≤ 93%) requiring hospitalization with or without intubation, in addition to the symptoms described for the COVID-19 positive participants who had moderate symptoms group.

You may not qualify if:

• Body Mass Index (BMI) ≥ 35 kg/m2;
• Pregnancy;
• Pain, swelling, dermal damage, deformity, or amputation in the regions to be examined;
• Diagnosis of ankylosing spondylitis, rheumatoid arthritis, severe heart disease, advanced chronic obstructive pulmonary disease, cognitive impairment, chemical dependency, psychiatric illness, or behavioral that makes it difficult to cooperate with the procedures.

Sponsors & Collaborators

• University of Brasilia: lead

Study Sites (1)

University of Brasilia

Brasília, Federal District, 72220-900, Brazil

RECRUITING

Related Publications (1)

• Almeida IDS, Ferreira LGJ, Vaz MA, Cipriano Junior G, de Resende MA, Vieira DCL, Costa RR, Babault N, Marqueti RC, Durigan JLQ. Fatigue and neuromuscular function in long COVID: A one-year follow-up study. PLoS One. 2025 Sep 24;20(9):e0332242. doi: 10.1371/journal.pone.0332242. eCollection 2025.

  PMID: 40991619 DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples to assess cytokines and matrix metalloproteinases (MMPs) involved in COVID-19 pathology.

MeSH Terms

Conditions

COVID-19; Fatigue

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• João LQ Durigan, PhD

  University of Brasilia

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rita CM Durigan, PhD

CONTACT

+55 61 3107-8450; marqueti@gmail.com

João LQ Durigan, PhD

CONTACT

+55 61 3107-8450; joaodurigan@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Physical Therapist, Assistant Professor

Study Record Dates

• First Submitted: July 6, 2021
• First Posted: July 14, 2021
• Study Start: August 24, 2021
• Primary Completion: August 30, 2024
• Study Completion: December 30, 2024
• Last Updated: December 5, 2023

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

BR (1)